Sign in to continue:

Saturday, April 4th, 2026

Value Partners Group Limited Board Meeting Scheduled for March 17, 2026 to Approve 2025 Final Results and Dividend Announcement 1

Key Points

  • Board Meeting Date: The Board of Value Partners Group Limited will convene on Tuesday, 17 March 2026.
  • Purpose: The primary agenda is to consider and approve the audited final results for the year ended 31 December 2025, as well as to discuss the possible payment of a final dividend.
  • Publication: The results and any dividend decision will be published following the meeting.
  • Directorate: The announcement also confirms the current composition of the Board, including executive, non-executive, and independent non-executive directors.

Important Information for Shareholders

  • Potential Dividend Announcement: The Board will consider the payment of a final dividend at the upcoming meeting. The declaration or omission of a dividend is a critical event for shareholders, as it can have a direct impact on the company’s share price and investor returns.
  • Audited Final Results Approval: The approval and subsequent publication of the Company’s audited financial results for 2025 are highly price-sensitive events. The financial performance of Value Partners Group Limited, including revenue, profit, and outlook, will be disclosed, which can significantly influence investor sentiment and share valuation.
  • Timing of Disclosure: Investors should anticipate the publication of the audited results and dividend decision shortly after the board meeting, which can lead to increased trading activity and volatility in the Company’s shares.
  • Board Composition: The current Board structure includes experienced executives and independent directors, which may reassure shareholders regarding corporate governance and decision-making integrity.

Details for Investors

Value Partners Group Limited, listed on the Hong Kong Stock Exchange (Stock Code: 806), has officially announced a forthcoming board meeting scheduled for Tuesday, 17 March 2026. At this meeting, the Board will review and approve the Company’s audited final results for the financial year ended 31 December 2025. This is a crucial disclosure for investors, as it will provide insight into the Company’s performance over the past year, including profitability, growth prospects, and management commentary.

Additionally, the Board will discuss the payment of a final dividend. The decision to declare a dividend, its amount, or any change in the dividend policy, is a significant event that can affect the share price. Shareholders and prospective investors should closely monitor this announcement, as dividend payments are a direct return on investment and reflect the Company’s financial health and confidence in future earnings.

Following the board meeting, the Company will publish its results and any dividend decision, which is expected to be a key event for market participants. Investors are advised to watch for these disclosures, as they may lead to significant movements in the share price and influence investment decisions.

The announcement also notes the current composition of the Board, comprising Ms. Lin Xianghong, Mr. Ouyang Xi, and Ms. Ng Chuk Fa, Nikita as Executive Directors; Dato’ Seri Cheah Cheng Hye as Non-Executive Director; and Dr. Chen Shih Ta Michael, Mr. Wong Poh Weng, and Mr. Lee Wai Wang Robert as Independent Non-executive Directors. This diverse and experienced Board is expected to provide sound governance and strategic direction for the Company.

Potential Impact on Share Price

  • The publication of audited financial results and any dividend declaration are events that can significantly impact the share price.
  • Positive financial performance and a robust dividend could drive share prices higher, while disappointing results or no dividend may lead to downside risk.
  • Investors should be prepared for potential volatility around the date of the announcement.

Disclaimer

This article is for information purposes only and does not constitute investment advice. Investors are urged to review official Company announcements and consult professional advisors before making any investment decisions. The information provided is based on company disclosures as of the date of publication and may be subject to change.

View VALUE PARTNERS Historical chart here



Ab&B Bio-Tech Receives FDA IND Approval for mRNA Mpox Vaccine—China’s First, World’s Third Candidate

Ab&B Bio-Tech Receives FDA IND Approval for mRNA Mpox Vaccin...

Wasion Holdings Secures BRL138 Million Exclusive Recloser Supply Contract with CEMIG in Brazil 12

Wasion Holdings Secures Major Brazilian Power Contract Was...

   Ad